{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:43:17Z","timestamp":1792640597580,"version":"4.5.0"},"reference-count":139,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004681","name":"Higher Education Commission, Pakistan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004681","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["314061271"],"award-info":[{"award-number":["314061271"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008769","name":"Julius-Maximilians-Universit\u00e4t W\u00fcrzburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008769","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s13318-021-00700-5","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T06:02:41Z","timestamp":1626847361000},"page":"575-593","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging"],"prefix":"10.1007","volume":"46","author":[{"given":"Malik Salman","family":"Haider","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taufiq","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Groll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Scherf-Clavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Kroiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5567-7404","authenticated-orcid":false,"given":"Robert","family":"Luxenhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,21]]},"reference":[{"issue":"1","key":"700_CR1","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1124\/pr.112.005660","volume":"65","author":"HD Williams","year":"2013","unstructured":"Williams HD, Trevaskis NL, Charman SA, Shanker RM, Charman WN, Pouton CW, et al. Strategies to address low drug solubility in discovery and development. Pharmacol Rev. 2013;65(1):315\u2013499.","journal-title":"Pharmacol Rev"},{"issue":"7","key":"700_CR2","first-page":"1","volume":"15","author":"S Ali","year":"2012","unstructured":"Ali S, Kolter K. Challenges and opportunities in oral formulation development. Am Pharm Rev. 2012;15(7):1.","journal-title":"Am Pharm Rev."},{"issue":"3","key":"700_CR3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3390\/pharmaceutics11030129","volume":"11","author":"B Homayun","year":"2019","unstructured":"Homayun B, Lin X, Choi H-J. Challenges and recent progress in oral drug delivery systems for biopharmaceuticals. Pharmaceutics. 2019;11(3):129.","journal-title":"Pharmaceutics"},{"issue":"5","key":"700_CR4","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.apsb.2015.07.003","volume":"5","author":"S Kalepu","year":"2015","unstructured":"Kalepu S, Nekkanti V. Insoluble drug delivery strategies: review of recent advances and business prospects. Acta Pharm Sin B. 2015;5(5):442\u201353.","journal-title":"Acta Pharm Sin B."},{"issue":"4","key":"700_CR5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1517\/17425247.4.4.403","volume":"4","author":"A Fahr","year":"2007","unstructured":"Fahr A, Liu X. Drug delivery strategies for poorly water-soluble drugs. Expert Opin Drug Deliv. 2007;4(4):403\u201316.","journal-title":"Expert Opin Drug Deliv"},{"issue":"3\u20134","key":"700_CR6","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.ejps.2006.04.016","volume":"29","author":"CW Pouton","year":"2006","unstructured":"Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci. 2006;29(3\u20134):278\u201387.","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"700_CR7","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1210\/er.2013-1029","volume":"35","author":"T Else","year":"2013","unstructured":"Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Caoili EM, et al. Adrenocortical carcinoma. Endocr Rev. 2013;35(2):282\u2013326.","journal-title":"Endocr Rev"},{"issue":"4","key":"700_CR8","first-page":"386","volume":"6","author":"S Hahner","year":"2005","unstructured":"Hahner S, Fassnacht M. Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs. 2005;6(4):386\u201394.","journal-title":"Curr Opin Investig Drugs"},{"issue":"10","key":"700_CR9","doi-asserted-by":"publisher","first-page":"383","DOI":"10.3733\/hilg.v42n10p383","volume":"42","author":"J Biggar","year":"1974","unstructured":"Biggar J, Riggs R. Apparent solubility of organochlorine insecticides in water at various temperatures. Hilgardia. 1974;42(10):383\u201391.","journal-title":"Hilgardia"},{"key":"700_CR10","first-page":"296","volume":"58","author":"R Moy","year":"1961","unstructured":"Moy R. Studies of the pharmacology of o, p\u2019DDD in man. J Lab Clin Med. 1961;58:296\u2013304.","journal-title":"J Lab Clin Med"},{"key":"700_CR11","doi-asserted-by":"crossref","unstructured":"Corso CR, Acco A, Bach C, Bonatto SJR, de Figueiredo BC, de Souza LM. Pharmacological profile and effects of mitotane in adrenocortical carcinoma. Br J Clin Pharmacol. 2020;87(7):2698\u20132710.","DOI":"10.1111\/bcp.14721"},{"key":"700_CR12","doi-asserted-by":"publisher","first-page":"821","DOI":"10.3389\/fgene.2019.00821","volume":"10","author":"W-H Xu","year":"2019","unstructured":"Xu W-H, Wu J, Wang J, Wan F-N, Wang H-K, Cao D-L, et al. Screening and identification of potential prognostic biomarkers in adrenocortical carcinoma. Front Genet. 2019;10:821.","journal-title":"Front Genet"},{"issue":"8","key":"700_CR13","doi-asserted-by":"publisher","first-page":"636","DOI":"10.14740\/jocmr3503w","volume":"10","author":"E Sharma","year":"2018","unstructured":"Sharma E, Dahal S, Sharma P, Bhandari A, Gupta V, Amgai B, et al. The characteristics and trends in adrenocortical carcinoma: a United States population based study. J Clin Med Res. 2018;10(8):636.","journal-title":"J Clin Med Res"},{"issue":"suppl 7","key":"700_CR14","doi-asserted-by":"publisher","first-page":"vii131","DOI":"10.1093\/annonc\/mds231","volume":"23","author":"A Berruti","year":"2012","unstructured":"Berruti A, Baudin E, Gelderblom H, Haak H, Porpiglia F, Fassnacht M, et al. Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(suppl 7):vii131\u20138.","journal-title":"Ann Oncol"},{"issue":"11","key":"700_CR15","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1016\/j.ejca.2013.02.034","volume":"49","author":"TM Kerkhofs","year":"2013","unstructured":"Kerkhofs TM, Verhoeven RH, Van der Zwan JM, Dieleman J, Kerstens MN, Links TP, et al. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer. 2013;49(11):2579\u201386.","journal-title":"Eur J Cancer"},{"issue":"27","key":"700_CR16","doi-asserted-by":"publisher","first-page":"4619","DOI":"10.1200\/JCO.2008.17.2775","volume":"27","author":"I Veytsman","year":"2009","unstructured":"Veytsman I, Nieman L, Fojo T. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J Clin Oncol. 2009;27(27):4619.","journal-title":"J Clin Oncol"},{"issue":"2","key":"700_CR17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.beem.2008.10.008","volume":"23","author":"M Fassnacht","year":"2009","unstructured":"Fassnacht M, Allolio B. Clinical management of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab. 2009;23(2):273\u201389.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"4","key":"700_CR18","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-18-0608","volume":"179","author":"M Fassnacht","year":"2018","unstructured":"Fassnacht M, Dekkers O, Else T, Baudin E, Berruti A, De Krijger RR, et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2018;179(4):G1\u201346.","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"700_CR19","first-page":"1259","volume":"2","author":"DR Mohan","year":"2018","unstructured":"Mohan DR, Lerario AM, Hammer GD. Therapeutic targets for adrenocortical carcinoma in the genomics era. JES. 2018;2(11):1259\u201374.","journal-title":"JES"},{"key":"700_CR20","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/s12020-019-02033-5","volume":"66","author":"SS Pereira","year":"2019","unstructured":"Pereira SS, Monteiro MP, Costa MM, Moreira \u00c2, Alves MG, Oliveira PF, et al. IGF2 role in adrenocortical carcinoma biology. Endocrine. 2019;66:326\u201337.","journal-title":"Endocrine"},{"issue":"8","key":"700_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0103744","volume":"9","author":"M Guillaud-Bataille","year":"2014","unstructured":"Guillaud-Bataille M, Ragazzon B, De Reynies A, Chevalier C, Francillard I, Barreau O, et al. IGF2 promotes growth of adrenocortical carcinoma cells, but its overexpression does not modify phenotypic and molecular features of adrenocortical carcinoma. PLoS ONE. 2014;9(8): e103744.","journal-title":"PLoS ONE"},{"issue":"6","key":"700_CR22","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.jamcollsurg.2018.01.051","volume":"226","author":"TC Brown","year":"2018","unstructured":"Brown TC, Nicolson NG, Korah R, Carling T. BCL9 upregulation in adrenocortical carcinoma: a novel Wnt\/\u03b2-catenin activating event driving adrenocortical malignancy. J Am Coll Surg. 2018;226(6):988\u201395.","journal-title":"J Am Coll Surg"},{"issue":"6","key":"700_CR23","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/ng.2953","volume":"46","author":"G Assi\u00e9","year":"2014","unstructured":"Assi\u00e9 G, Letouz\u00e9 E, Fassnacht M, Jouinot A, Luscap W, Barreau O, et al. Integrated genomic characterization of adrenocortical carcinoma. Nat Genet. 2014;46(6):607\u201312.","journal-title":"Nat Genet"},{"issue":"5","key":"700_CR24","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ccell.2016.04.002","volume":"29","author":"S Zheng","year":"2016","unstructured":"Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA, et al. Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell. 2016;29(5):723\u201336.","journal-title":"Cancer Cell"},{"issue":"3","key":"700_CR25","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1530\/EC-18-0526","volume":"8","author":"W Wang","year":"2019","unstructured":"Wang W, Han R, Ye L, Xie J, Tao B, Sun F, et al. Adrenocortical carcinoma in patients with MEN1: a kindred report and review of the literature. Endocr Connect. 2019;8(3):230\u20138.","journal-title":"Endocr Connect"},{"issue":"3","key":"700_CR26","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1677\/erc.1.01029","volume":"12","author":"D Schteingart","year":"2005","unstructured":"Schteingart D, Doherty G, Gauger P, Giordano T, Hammer G, Korobkin M, et al. Management of patients with adrenal cancer: Recommendations of an international consensus conference. Endocr-Relat Cancer. 2005;12(3):667\u201380.","journal-title":"Endocr-Relat Cancer."},{"issue":"23","key":"700_CR27","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","volume":"366","author":"M Fassnacht","year":"2012","unstructured":"Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366(23):2189\u201397.","journal-title":"N Engl J Med"},{"issue":"6","key":"700_CR28","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nrendo.2010.235","volume":"7","author":"M Fassnacht","year":"2011","unstructured":"Fassnacht M, Lib\u00e9 R, Kroiss M, Allolio B. Adrenocortical carcinoma: a clinician\u2019s update. Nat Rev Endocrinol. 2011;7(6):323.","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"700_CR29","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.humpath.2014.11.015","volume":"46","author":"M Pennanen","year":"2015","unstructured":"Pennanen M, Heiskanen I, Sane T, Remes S, Mustonen H, Haglund C, et al. Helsinki score\u2014a novel model for prediction of metastases in adrenocortical carcinomas. Hum Pathol. 2015;46(3):404\u201310.","journal-title":"Hum Pathol"},{"issue":"3","key":"700_CR30","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1210\/endo-62-3-334","volume":"62","author":"C Cueto","year":"1958","unstructured":"Cueto C, Brown J. Biological studies on an adrenocorticolytic agent and the isolation of the active components. Endocrinology. 1958;62(3):334\u20139.","journal-title":"Endocrinology"},{"issue":"3","key":"700_CR31","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1210\/endo-62-3-326","volume":"62","author":"C Cueto","year":"1958","unstructured":"Cueto C, Brown J. The chemical fractionation of an adrenocorticolytic drug. Endocrinology. 1958;62(3):326\u201333.","journal-title":"Endocrinology"},{"issue":"11","key":"700_CR32","doi-asserted-by":"publisher","first-page":"566","DOI":"10.3390\/pharmaceutics11110566","volume":"11","author":"Y Cazaubon","year":"2019","unstructured":"Cazaubon Y, Talineau Y, Feliu C, Konecki C, Russello J, Mathieu O, et al. Population pharmacokinetics modelling and simulation of mitotane in patients with adrenocortical carcinoma: an individualized dose regimen to target all patients at three months? Pharmaceutics. 2019;11(11):566.","journal-title":"Pharmaceutics"},{"issue":"4","key":"700_CR33","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.jamcollsurg.2015.12.013","volume":"222","author":"LM Postlewait","year":"2016","unstructured":"Postlewait LM, Ethun CG, Tran TB, Prescott JD, Pawlik TM, Wang TS, et al. Outcomes of adjuvant mitotane after resection of adrenocortical carcinoma: a 13-institution study by the US Adrenocortical Carcinoma Group. J Am Coll Surg. 2016;222(4):480\u201390.","journal-title":"J Am Coll Surg"},{"issue":"4","key":"700_CR34","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1210\/jc.2016-2894","volume":"102","author":"A Berruti","year":"2017","unstructured":"Berruti A, Grisanti S, Pulzer A, Claps M, Daffara F, Loli P, et al. Long-term outcomes of adjuvant mitotane therapy in patients with radically resected adrenocortical carcinoma. J Clin Endocrinol Metab. 2017;102(4):1358\u201365.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"700_CR35","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1365-2125.2006.02579.x","volume":"61","author":"R Joppi","year":"2006","unstructured":"Joppi R, Bertele V, Garattini S. Orphan drug development is progressing too slowly. Br J Clin Pharmacol. 2006;61(3):355\u201360.","journal-title":"Br J Clin Pharmacol"},{"key":"700_CR36","unstructured":"European Medicine Agency Website. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu302102. Accessed 26 Jun 2021."},{"issue":"5","key":"700_CR37","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/j.1365-2125.2009.03369.x","volume":"67","author":"R Joppi","year":"2009","unstructured":"Joppi R, Bertele V, Garattini S. Orphan drug development is not taking off. Br J Clin Pharmacol. 2009;67(5):494\u2013502.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"700_CR38","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40618-013-0049-2","volume":"37","author":"M Terzolo","year":"2014","unstructured":"Terzolo M, Daffara F, Ardito A, Zaggia B, Basile V, Ferrari L, et al. Management of adrenal cancer: a 2013 update. J Endocrinol Investig. 2014;37(3):207\u201317.","journal-title":"J Endocrinol Investig."},{"key":"700_CR39","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.coemr.2019.08.010","volume":"8","author":"A Calabrese","year":"2019","unstructured":"Calabrese A, Puglisi S, Basile V, Perotti P, Terzolo M. Mitotane: new facts for an old drug. Curr Opinion Endocr Metab Res. 2019;8:145\u201351.","journal-title":"Curr Opinion Endocr Metab Res."},{"issue":"12","key":"700_CR40","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.2217\/pgs.12.116","volume":"13","author":"A Zsippai","year":"2012","unstructured":"Zsippai A, Szab\u00f3 DR, T\u00f6mb\u00f6l Z, Szab\u00f3 PM, \u00c9der K, P\u00e1llinger \u00c9, et al. Effects of mitotane on gene expression in the adrenocortical cell line NCI-H295R: a microarray study. Pharmacogenomics. 2012;13(12):1351\u201361.","journal-title":"Pharmacogenomics"},{"issue":"1","key":"700_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1677\/ERC-07-0003","volume":"15","author":"A Stigliano","year":"2008","unstructured":"Stigliano A, Cerquetti L, Borro M, Gentile G, Bucci B, Misiti S, et al. Modulation of proteomic profile in H295R adrenocortical cell line induced by mitotane. Endocr-Relat Cancer. 2008;15(1):1.","journal-title":"Endocr-Relat Cancer."},{"issue":"4","key":"700_CR42","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1210\/jcem-36-4-730","volume":"36","author":"RD Brown","year":"1973","unstructured":"Brown RD, Nicholson WE, Chick WT, Strott CA. Effect of o,p\u2019DDD on human adrenal steroid ll\u03b2-hydroxylation activity. J Clin Endocrinol Metab. 1973;36(4):730\u20133.","journal-title":"J Clin Endocrinol Metab"},{"key":"700_CR43","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1530\/ERC-12-0217","volume":"20","author":"PM Van Koetsveld","year":"2013","unstructured":"Van Koetsveld PM, Vitale G, Feelders RA, Waaijers M, Sprij-Mooij DM, De Krijger RR, et al. Interferon-b is a potent inhibitor of cell growth and cortisol production in vitro and sensitizes human adrenocortical carcinoma cells to mitotane. Endocr-Relat Cancer. 2013;20:443\u201354.","journal-title":"Endocr-Relat Cancer."},{"issue":"3","key":"700_CR44","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3892\/mmr.2012.1244","volume":"7","author":"TP Lehmann","year":"2013","unstructured":"Lehmann TP, Wrzesi\u0144ski T, Jagodzi\u0144ski PP. The effect of mitotane on viability, steroidogenesis and gene expression in NCI-H295R adrenocortical cells. Mol Med Rep. 2013;7(3):893\u2013900.","journal-title":"Mol Med Rep"},{"issue":"4","key":"700_CR45","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1530\/ERC-13-0150","volume":"20","author":"G Poli","year":"2013","unstructured":"Poli G, Guasti D, Rapizzi E, Fucci R, Canu L, Bandinelli A, et al. Morphofunctional effects of mitotane on mitochondria in human adrenocortical cancer cells. Endocr-Relat Cancer. 2013;20(4):537\u201350.","journal-title":"Endocr-Relat Cancer."},{"issue":"11","key":"700_CR46","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1210\/en.2015-1367","volume":"156","author":"S Sbiera","year":"2015","unstructured":"Sbiera S, Leich E, Liebisch G, Sbiera I, Schirbel A, Wiemer L, et al. Mitotane inhibits sterol-O-acyl transferase 1 triggering lipid-mediated endoplasmic reticulum stress and apoptosis in adrenocortical carcinoma cells. Endocrinology. 2015;156(11):3895\u2013908.","journal-title":"Endocrinology"},{"key":"700_CR47","doi-asserted-by":"publisher","first-page":"P019","DOI":"10.1055\/s-0034-1372036","volume":"122","author":"S Sbiera","year":"2014","unstructured":"Sbiera S, Wiemer L, Leich E, Gehl A, Gardill F, Ronchi CL, et al. Mitotane induces endoplasmic reticulum stress triggering apoptosis and decrease of steroid hormone synthesis. Exp Clin Endocrinol Diabetes. 2014;122:P019.","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"8","key":"700_CR48","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1210\/clinem\/dgaa293","volume":"105","author":"I Weigand","year":"2020","unstructured":"Weigand I, Altieri B, Lacombe AM, Basile V, Kircher S, Landwehr L-S, et al. Expression of SOAT1 in adrenocortical carcinoma and response to mitotane monotherapy: an ENSAT multicenter study. J Clin Endocrinol Metab. 2020;105(8):2642\u201353.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"700_CR49","doi-asserted-by":"publisher","first-page":"3873","DOI":"10.1210\/en.2015-1796","volume":"156","author":"E Lalli","year":"2015","unstructured":"Lalli E. Mitotane revisited: a new target for an old drug. Endocrinology. 2015;156(11):3873\u20135.","journal-title":"Endocrinology"},{"issue":"12","key":"700_CR50","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3390\/cancers12010247","volume":"4","author":"AMF Lacombe","year":"2020","unstructured":"Lacombe AMF, Soares IC, Charchar HDS, Brondani VB, Neto JEB, Tanno F, et al. SAT-165 sterol O-acyl transferase 1 as a prognostic marker of adrenocortical carcinoma. Cancers. 2020;4(12):247.","journal-title":"Cancers"},{"issue":"11","key":"700_CR51","first-page":"631","volume":"11","author":"D Holmes","year":"2015","unstructured":"Holmes D. Cancer target of mitotane identified. Nat Rev Endocrinol. 2015;11(11):631.","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"700_CR52","doi-asserted-by":"publisher","first-page":"62","DOI":"10.17925\/EE.2018.14.2.62","volume":"14","author":"RM Paragliola","year":"2018","unstructured":"Paragliola RM, Torino F, Papi G, Locantore P, Pontecorvi A, Corsello SM. Role of mitotane in adrenocortical carcinoma\u2013review and state of the art. Eur Endocrinol. 2018;14(2):62\u20136.","journal-title":"Eur Endocrinol."},{"issue":"3","key":"700_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2020.101415","volume":"34","author":"S Puglisi","year":"2020","unstructured":"Puglisi S, Calabrese A, Basile V, Pia A, Reimondo G, Perotti P, et al. New perspectives for mitotane treatment of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab. 2020;34(3): 101415.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"700_CR54","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/BF00258213","volume":"7","author":"A Moolenaar","year":"1981","unstructured":"Moolenaar A, Van Slooten H, Van Seters A, Smeenk D. Blood levels of o, p\u2032-DDD following administration in various vehicles after a single dose and during long-term treatment. Cancer Chemother Pharmacol. 1981;7(1):51\u20134.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"700_CR55","first-page":"32","volume":"27","author":"A Grid'ko","year":"1981","unstructured":"Grid\u2019ko A, Borzunov E, Komissarenko I, Perepelitsa N. Pharmacokinetics of chlodithane tablets in the treatment of Cushing\u2019s syndrome. Probl Endokrnol. 1981;27(2):32\u20135.","journal-title":"Probl Endokrnol."},{"issue":"2","key":"700_CR56","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00280-007-0468-x","volume":"61","author":"V Hermansson","year":"2008","unstructured":"Hermansson V, Cantillana T, Hovander L, Bergman \u00c5, Ljungvall K, Magnusson U, et al. Pharmacokinetics of the adrenocorticolytic compounds 3-methylsulphonyl-DDE and o, p\u2032-DDD (mitotane) in Minipigs. Cancer Chemother Pharmacol. 2008;61(2):267\u201374.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"700_CR57","first-page":"482","volume":"5","author":"F Martz","year":"1977","unstructured":"Martz F, Straw JA. The in vitro metabolism of 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2, 2-dichloroethane (o, p\u2019-DDD) by dog adrenal mitochondria and metabolite covalent binding to mitochondrial macromolecules: a possible mechanism for the adrenocorticolytic effect. Drug Metab Dispos. 1977;5(5):482\u20136.","journal-title":"Drug Metab Dispos"},{"issue":"1\u20132","key":"700_CR58","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/0009-2797(89)90063-X","volume":"70","author":"B-O Lund","year":"1989","unstructured":"Lund B-O, Bergman \u00c5, Brandt I. In vitro macromolecular binding of 2-(2-chlorophenyl)-2-(4-chlorophenyl)-1, 1-dichloroethane (o, p\u2032-DDD) in the mouse lung and liver. Chem Biol Interact. 1989;70(1\u20132):63\u201372.","journal-title":"Chem Biol Interact"},{"issue":"2","key":"700_CR59","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/jps.2600840203","volume":"84","author":"W Cai","year":"1995","unstructured":"Cai W, Counsell R, Djanegara T, Schteingart D, Sinsheimer J, Wotring L. Metabolic activation and binding of mitotane in adrenal cortex homogenates. J Pharm Sci. 1995;84(2):134\u20138.","journal-title":"J Pharm Sci"},{"issue":"11","key":"700_CR60","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1002\/bmc.2696","volume":"26","author":"A Mornar","year":"2012","unstructured":"Mornar A, Serti\u0107 M, Turk N, Nigovi\u0107 B, Kor\u0161i\u0107 M. Simultaneous analysis of mitotane and its main metabolites in human blood and urine samples by SPE-HPLC technique. Biomed Chromatogr. 2012;26(11):1308\u201314.","journal-title":"Biomed Chromatogr"},{"issue":"9","key":"700_CR61","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1289\/ehp.6141","volume":"111","author":"S Chu","year":"2003","unstructured":"Chu S, Covaci A, Jacobs W, Haraguchi K, Schepens P. Distribution of methyl sulfone metabolites of polychlorinated biphenyls and p, p\u2019-DDE in human tissues. Environ Health Perspect. 2003;111(9):1222\u20137.","journal-title":"Environ Health Perspect"},{"issue":"2","key":"700_CR62","first-page":"357","volume":"72","author":"J Finnegan","year":"1949","unstructured":"Finnegan J, Haag H, Larson P. Tissue distribution and elimination of DDD and DDT following oral administration to dogs and rats. SEBM. 1949;72(2):357\u201360.","journal-title":"SEBM."},{"issue":"3","key":"700_CR63","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1530\/EJE-15-0946","volume":"174","author":"M Kroiss","year":"2016","unstructured":"Kroiss M, Plonn\u00e9 D, Kendl S, Schirmer D, Ronchi CL, Schirbel A, et al. Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma. Eur J Endocrinol. 2016;174(3):343\u201353.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"700_CR64","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3390\/life11030266","volume":"11","author":"S Allegra","year":"2021","unstructured":"Allegra S, Puglisi S, Brescia I, Chiara F, Basile V, Calabrese A, et al. Sex differences on mitotane concentration and treatment outcome in patients with adrenocortical carcinoma. Life. 2021;11(3):266.","journal-title":"Life"},{"issue":"14","key":"700_CR65","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1080\/10826076.2015.1057645","volume":"38","author":"B Jan\u010di\u0107-Stojanovi\u0107","year":"2015","unstructured":"Jan\u010di\u0107-Stojanovi\u0107 B, Vemi\u0107 S, Elezovi\u0107 V, Petrovi\u0107 A, Sinadinovi\u0107 Z, Ivanovi\u0107 D, et al. Development of new liquid chromatographic method for mitotane and its metabolites determination in human plasma employing design of experiments methodology. J Liq Chrom Relat Tech. 2015;38(14):1371\u20138.","journal-title":"J Liq Chrom Relat Tech."},{"issue":"23","key":"700_CR66","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1016\/j.jchromb.2011.06.001","volume":"879","author":"MB Garg","year":"2011","unstructured":"Garg MB, Sakoff JA, Ackland SP. A simple HPLC method for plasma level monitoring of mitotane and its two main metabolites in adrenocortical cancer patients. J Chromatogr B. 2011;879(23):2201\u20135.","journal-title":"J Chromatogr B"},{"issue":"3","key":"700_CR67","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3109\/00498250903470230","volume":"40","author":"V Asp","year":"2010","unstructured":"Asp V, Cantillana T, Bergman \u00c5, Brandt I. Chiral effects in adrenocorticolytic action of o, p\u2032-DDD (mitotane) in human adrenal cells. Xenobiotica. 2010;40(3):177\u201383.","journal-title":"Xenobiotica"},{"issue":"4","key":"700_CR68","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/BF00685956","volume":"29","author":"D Gebhardt","year":"1992","unstructured":"Gebhardt D, Moolenaar A, Seters VA, Van Der Velde E, Leuven JG. The distribution of o, p\u2032-DDD (Mitotane) among serum lipoproteins in normo-and hypertriglyceridemia. Cancer Chemother Pharmacol. 1992;29(4):331\u20134.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"700_CR69","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/0041-008X(85)90266-2","volume":"77","author":"RC Pohland","year":"1985","unstructured":"Pohland RC, Counsell RE. The role of high density lipoproteins in the biodistribution of two radioiodinated probes in the rat. Toxicol Appl Pharmacol. 1985;77(1):47\u201357.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"8","key":"700_CR70","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1210\/JC.2015-2080","volume":"100","author":"S Hescot","year":"2015","unstructured":"Hescot S, Seck A, Guerin M, Cockenpot F, Huby T, Broutin S, et al. Lipoprotein-free mitotane exerts high cytotoxic activity in adrenocortical carcinoma. J Clin Endocrinol Metab. 2015;100(8):2890\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"700_CR71","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s12672-014-0189-7","volume":"5","author":"S Hescot","year":"2014","unstructured":"Hescot S, Paci A, Seck A, Slama A, Viengchareun S, Trabado S, et al. The lack of antitumor effects of o, p\u2032 DDA excludes its role as an active metabolite of mitotane for adrenocortical carcinoma treatment. Horm Cancer. 2014;5(5):312\u201323.","journal-title":"Horm Cancer."},{"issue":"1","key":"700_CR72","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/FTD.0000000000000102","volume":"37","author":"TM Kerkhofs","year":"2015","unstructured":"Kerkhofs TM, Derijks LJ, Ettaieb H, Den Hartigh J, Neef K, Gelderblom H, et al. Development of a pharmacokinetic model of mitotane: toward personalized dosing in adrenocortical carcinoma. Ther Drug Monit. 2015;37(1):58\u201365.","journal-title":"Ther Drug Monit"},{"issue":"5","key":"700_CR73","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1530\/EJE-18-0342","volume":"179","author":"U Arshad","year":"2018","unstructured":"Arshad U, Taubert M, Kurlbaum M, Frechen S, Herterich S, Megerle F, et al. Enzyme autoinduction by mitotane supported by population pharmacokinetic modelling in a large cohort of adrenocortical carcinoma patients. Eur J Endocrinol. 2018;179(5):287\u201397.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"700_CR74","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1007\/s12020-014-0517-2","volume":"49","author":"D Theile","year":"2015","unstructured":"Theile D, Haefeli WE, Weiss J. Effects of adrenolytic mitotane on drug elimination pathways assessed in vitro. Endocrine. 2015;49(3):842\u201353.","journal-title":"Endocrine"},{"issue":"1","key":"700_CR75","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3109\/03602532.2012.743560","volume":"45","author":"MW Sinz","year":"2013","unstructured":"Sinz MW. Evaluation of pregnane X receptor (PXR)-mediated CYP3A4 drug-drug interactions in drug development. Drug Metab Rev. 2013;45(1):3\u201314.","journal-title":"Drug Metab Rev"},{"issue":"2","key":"700_CR76","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S0034-5288(18)30766-5","volume":"43","author":"A Watson","year":"1987","unstructured":"Watson A, Rijnberk A, Moolenaar A. Systemic availability of o, p\u2019-DDD in normal dogs, fasted and fed, and in dogs with hyperadrenocorticism. Res Vet Sci. 1987;43(2):160\u20135.","journal-title":"Res Vet Sci"},{"issue":"6","key":"700_CR77","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1210\/jc.2010-2676","volume":"96","author":"IG Hermsen","year":"2011","unstructured":"Hermsen IG, Fassnacht M, Terzolo M, Houterman S, den Hartigh J, Leboulleux S, et al. Plasma concentrations of o, p\u2032 DDD, o, p\u2032 DDA, and o, p\u2032 DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J Clin Endocrinol Metab. 2011;96(6):1844\u201351.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"700_CR78","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1530\/EJE-13-0242","volume":"169","author":"M Terzolo","year":"2013","unstructured":"Terzolo M, Baudin A, Ardito A, Kroiss M, Leboulleux S, Daffara F, et al. Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection. Eur J Endocrinol. 2013;169(3):263\u201370.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"700_CR79","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1210\/jc.2017-02591","volume":"103","author":"F Megerle","year":"2018","unstructured":"Megerle F, Herrmann W, Schloetelburg W, Ronchi CL, Pulzer A, Quinkler M, et al. Mitotane monotherapy in patients with advanced adrenocortical carcinoma. J Clin Endocrinol Metab. 2018;103(4):1686\u201395.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"700_CR80","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1124\/dmd.30.2.113","volume":"30","author":"S Kitamura","year":"2002","unstructured":"Kitamura S, Shimizu Y, Shiraga Y, Yoshida M, Sugihara K, Ohta S. Reductive metabolism of p, p\u2032-DDT and o, p\u2032-DDT by rat liver cytochrome P450. Drug Metab Dispos. 2002;30(2):113\u20138.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"700_CR81","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1530\/EJE-10-0956","volume":"164","author":"NP van Erp","year":"2011","unstructured":"van Erp NP, Guchelaar HJ, Ploeger BA, Romijn JA, den Hartigh J, Gelderblom H. Mitotane has a strong and a durable inducing effect on CYP3A4 activity. Eur J Endocrinol. 2011;164(4):621\u20136.","journal-title":"Eur J Endocrinol"},{"key":"700_CR82","first-page":"1","volume":"60","author":"A Yin","year":"2020","unstructured":"Yin A, Ettaieb MH, Swen JJ, van Deun L, Kerkhofs TM, van der Straaten RJ, et al. Population pharmacokinetic and pharmacogenetic analysis of mitotane in patients with adrenocortical carcinoma: towards individualized dosing. Clin Pharmacokinet. 2020;60:1\u201314.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"700_CR83","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1530\/EJE-18-0342","volume":"179","author":"U Arshad","year":"2018","unstructured":"Arshad U, Taubert M, Kurlbaum M, Frechen S, Herterich S, Megerle F, et al. Enzyme autoinduction by mitotane supported by population pharmacokinetic modeling in a large cohort of adrenocortical carcinoma patients. Eur J Endocrinol. 2018;179(5):287\u201397.","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"700_CR84","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/bjc.1994.183","volume":"69","author":"H Haak","year":"1994","unstructured":"Haak H, Hermans J, Van de Velde C, Lentjes E, Goslings B, Fleuren G, et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer. 1994;69(5):947.","journal-title":"Br J Cancer"},{"issue":"12","key":"700_CR85","doi-asserted-by":"publisher","first-page":"4759","DOI":"10.1210\/jc.2013-2281","volume":"98","author":"T Kerkhofs","year":"2013","unstructured":"Kerkhofs T, Baudin E, Terzolo M, Allolio B, Chadarevian R, Mueller H, et al. Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98(12):4759\u201367.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"700_CR86","doi-asserted-by":"publisher","first-page":"740","DOI":"10.3390\/cancers12030740","volume":"12","author":"S Puglisi","year":"2020","unstructured":"Puglisi S, Calabrese A, Basile V, Ceccato F, Scaroni C, Altieri B, et al. Mitotane concentrations influence outcome in patients with advanced adrenocortical carcinoma. Cancers. 2020;12(3):740.","journal-title":"Cancers"},{"issue":"1","key":"700_CR87","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/j.1365-2265.2005.02403.x","volume":"64","author":"A Faggiano","year":"2006","unstructured":"Faggiano A, Leboulleux S, Young J, Schlumberger M, Baudin E. Rapidly progressing high o, p\u2019DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results. Clin Endocrinol. 2006;64(1):110\u20133.","journal-title":"Clin Endocrinol"},{"issue":"6","key":"700_CR88","first-page":"793","volume":"56","author":"O Neuman","year":"2001","unstructured":"Neuman O, Bruckert E, Chadarevian R, Jacob N, Turpin G. Hepatotoxicity of a synthetic cortisol antagonist: OP\u2019DDD (mitotane). Therapie. 2001;56(6):793\u20137.","journal-title":"Therapie"},{"key":"700_CR89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/624962","volume":"2013","author":"H Shawa","year":"2013","unstructured":"Shawa H, Deniz F, Bazerbashi H, Hernandez M, Vassilopoulou-Sellin R, Jimenez C, et al. Mitotane-induced hyperlipidemia: a retrospective cohort study. Int J Endocrinol. 2013;2013:1\u20137.","journal-title":"Int J Endocrinol."},{"key":"700_CR90","doi-asserted-by":"crossref","unstructured":"Oddie PD, Albert BB, Hofman PL, Jefferies C, Laughton S, Carter PJ. Mitotane in the treatment of childhood adrenocortical carcinoma: a potent endocrine disruptor. Endocrinol Diabetes Metab Case Rep. 2018, 18-0059.","DOI":"10.1530\/EDM-18-0059"},{"issue":"3","key":"700_CR91","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1634\/theoncologist.2017-0426","volume":"23","author":"E Pape","year":"2018","unstructured":"Pape E, Feliu C, Y\u00e9l\u00e9h\u00e9-Okouma M, Colling N, Djerada Z, Gambier N, et al. High-dose mitotane-induced encephalopathy in the treatment of adrenocortical carcinoma. Oncologist. 2018;23(3):389.","journal-title":"Oncologist"},{"issue":"3","key":"700_CR92","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1297\/cpe.17.71","volume":"17","author":"T Goto","year":"2008","unstructured":"Goto T, Miyako K, Kuromaru R, Ihara K, Torisu H, Sanefuji M, et al. Case report: adjuvant therapy with a high dose of mitotane for adrenocortical carcinoma in a 4-year-old boy. Clin Pediatr Endocrinol. 2008;17(3):71\u20134.","journal-title":"Clin Pediatr Endocrinol"},{"issue":"4","key":"700_CR93","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/cen.12868","volume":"84","author":"M Russo","year":"2016","unstructured":"Russo M, Scollo C, Pellegriti G, Cotta OR, Squatrito S, Frasca F, et al. Mitotane treatment in patients with adrenocortical cancer causes central hypothyroidism. Clin Endocrinol. 2016;84(4):614\u20139.","journal-title":"Clin Endocrinol"},{"issue":"17","key":"700_CR94","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1007\/s00216-019-01868-1","volume":"411","author":"B Friedl","year":"2019","unstructured":"Friedl B, Kurlbaum M, Kroiss M, Fassnacht M, Scherf-Clavel O. A method for the minimally invasive drug monitoring of mitotane by means of volumetric absorptive microsampling for a home-based therapeutic drug monitoring. Anal Bioanal Chem. 2019;411(17):3951\u201362.","journal-title":"Anal Bioanal Chem"},{"issue":"10","key":"700_CR95","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1007\/s11095-008-9637-9","volume":"25","author":"R Takano","year":"2008","unstructured":"Takano R, Furumoto K, Shiraki K, Takata N, Hayashi Y, Aso Y, et al. Rate-limiting steps of oral absorption for poorly water-soluble drugs in dogs; prediction from a miniscale dissolution test and a physiologically-based computer simulation. Pharm Res. 2008;25(10):2334\u201344.","journal-title":"Pharm Res"},{"issue":"2","key":"700_CR96","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/BF00265384","volume":"9","author":"HV Slooten","year":"1982","unstructured":"Slooten HV, Van Seters A, Smeenk D, Moolenaar A. O, p\u2032-DDD (mitotane) levels in plasma and tissues during chemotherapy and at autopsy. Cancer Chemother Pharmacol. 1982;9(2):85\u20138.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"700_CR97","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.colsurfb.2011.03.015","volume":"85","author":"Y-H Lin","year":"2011","unstructured":"Lin Y-H, Chen Y-S, Wu T-C, Chen L-J. Enhancement of dissolution rate of mitotane and warfarin prepared by using microemulsion systems. Colloids Surf. 2011;85(2):366\u201372.","journal-title":"Colloids Surf"},{"issue":"4","key":"700_CR98","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3109\/03639040903225083","volume":"36","author":"D Attivi","year":"2010","unstructured":"Attivi D, Ajana I, Astier A, Demore B, Gibaud S. Development of microemulsion of mitotane for improvement of oral bioavailability. Drug Dev Ind Pharm. 2010;36(4):421\u20137.","journal-title":"Drug Dev Ind Pharm"},{"key":"700_CR99","unstructured":"Battung F, Hassan E, Sansoe L. US8486445B2; 2013."},{"issue":"1\u20132","key":"700_CR100","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0168-3659(01)00432-1","volume":"76","author":"M Trotta","year":"2001","unstructured":"Trotta M, Gallarate M, Pattarino F, Morel S. Emulsions containing partially water-miscible solvents for the preparation of drug nanosuspensions. J Control Release. 2001;76(1\u20132):119\u201328.","journal-title":"J Control Release"},{"issue":"34","key":"700_CR101","doi-asserted-by":"publisher","first-page":"5854","DOI":"10.2174\/092986712804143376","volume":"19","author":"F Menaa","year":"2012","unstructured":"Menaa F, Menaa B. Development of mitotane lipid nanocarriers and enantiomers: two-in-one solution to efficiently treat adrenocortical carcinoma. Curr Med Chem. 2012;19(34):5854\u201362.","journal-title":"Curr Med Chem"},{"issue":"2","key":"700_CR102","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.chemosphere.2009.03.050","volume":"76","author":"T Cantillana","year":"2009","unstructured":"Cantillana T, Lindstr\u00f6m V, Eriksson L, Brandt I, Bergman \u00c5. Interindividual differences in o, p\u2032-DDD enantiomer kinetics examined in G\u00f6ttingen minipigs. Chemosphere. 2009;76(2):167\u201372.","journal-title":"Chemosphere"},{"issue":"4","key":"700_CR103","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1080\/01496395.2011.617805","volume":"47","author":"F Antelo","year":"2012","unstructured":"Antelo F, Santana CC, Moitinho Alves TL, Barreto AG Jr. Thermodynamic study of enantioseparation of mitotane by supercritical fluid chromatography. Sep Sci Technol. 2012;47(4):636\u201340.","journal-title":"Sep Sci Technol"},{"issue":"3","key":"700_CR104","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3109\/10837450.2011.614250","volume":"18","author":"P Severino","year":"2013","unstructured":"Severino P, Souto EB, Pinho SC, Santana MH. Hydrophilic coating of mitotane-loaded lipid nanoparticles: preliminary studies for mucosal adhesion. Pharm Dev Technol. 2013;18(3):577\u201381.","journal-title":"Pharm Dev Technol"},{"issue":"2","key":"700_CR105","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1166\/jcsb.2013.1044","volume":"2","author":"CRC Grando","year":"2013","unstructured":"Grando CRC, Guimar\u00e3es CA, Mercuri LP, Matos JDR, Santana MHA. Preparation and characterization of solid lipid nanoparticles loaded with racemic mitotane. J Colloid Sci Biotechnol. 2013;2(2):140\u20135.","journal-title":"J Colloid Sci Biotechnol."},{"issue":"3","key":"700_CR106","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.pharma.2013.02.001","volume":"71","author":"R Alfonsi","year":"2013","unstructured":"Alfonsi R, Attivi D, Astier A, Socha M, Morice S, Gibaud S. Characterization of mitotane (o, p\u2032-DDD)\u2013cyclodextrin inclusion complexes: phase-solubility method and NMR. Ann Pharm Fr. 2013;71(3):186\u201392.","journal-title":"Ann Pharm Fr"},{"issue":"8","key":"700_CR107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10837450.2020.1762645","volume":"25","author":"P Zancanella","year":"2020","unstructured":"Zancanella P, Oliveira D, de Oliveira B, Woiski T, Pinto C, Santana M, et al. Mitotane liposomes for potential treatment of adrenal cortical carcinoma: ex vivo intestinal permeation and in vivo bioavailability. Pharm Dev Technol. 2020;25(8):1\u201336.","journal-title":"Pharm Dev Technol"},{"key":"700_CR108","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/978-3-319-42609-9_6","volume-title":"Injectable formulations of poorly water-soluble drugs. Formulating poorly water soluble drugs","author":"YW Naguib","year":"2016","unstructured":"Naguib YW, O\u2019Mary HL, Cui Z, Watts AB. Injectable formulations of poorly water-soluble drugs. Formulating poorly water soluble drugs. New York: Springer; 2016. p. 257\u201393."},{"key":"700_CR109","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ejps.2015.12.008","volume":"87","author":"M Kuentz","year":"2016","unstructured":"Kuentz M, Holm R, Elder DP. Methodology of oral formulation selection in the pharmaceutical industry. Eur J Pharm Sci. 2016;87:136\u201363.","journal-title":"Eur J Pharm Sci"},{"key":"700_CR110","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.biomaterials.2018.05.022","volume":"178","author":"T Lorson","year":"2018","unstructured":"Lorson T, L\u00fcbtow MM, Wegener E, Haider MS, Borova S, Nahm D, et al. Poly (2-oxazoline)s based biomaterials: a comprehensive and critical update. Biomaterials. 2018;178:204\u201380.","journal-title":"Biomaterials"},{"issue":"1","key":"700_CR111","doi-asserted-by":"publisher","first-page":"1900178","DOI":"10.1002\/mabi.201900178","volume":"20","author":"MS Haider","year":"2020","unstructured":"Haider MS, Schreiner J, Kendl S, Kroiss M, Luxenhofer R. A micellar mitotane formulation with high drug-loading and solubility: physico-chemical characterization and cytotoxicity studies in 2D and 3D in vitro tumor models. Macromol Biosci. 2020;20(1):1900178.","journal-title":"Macromol Biosci"},{"key":"700_CR112","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jconrel.2019.04.014","volume":"303","author":"MM L\u00fcbtow","year":"2019","unstructured":"L\u00fcbtow MM, Nelke LC, Seifert J, K\u00fchnemundt J, Sahay G, Dandekar G, et al. Drug induced micellization into ultra-high capacity and stable curcumin nanoformulations: physico-chemical characterization and evaluation in 2D and 3D in vitro models. J Control Release. 2019;303:162\u201380.","journal-title":"J Control Release"},{"key":"700_CR113","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1021\/acs.biomac.9b00618","volume":"20","author":"MM L\u00fcbtow","year":"2019","unstructured":"L\u00fcbtow MM, Haider MS, Kirsch M, Klisch S, Luxenhofer R. Like dissolves like? A comprehensive evaluation of partial solubility parameters to predict polymer-drug compatibility in ultra-high drug loaded polymer micelles. Biomacromol. 2019;20:3041\u201356.","journal-title":"Biomacromol"},{"issue":"7","key":"700_CR114","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1021\/acs.biomac.8b00708","volume":"19","author":"L Hahn","year":"2018","unstructured":"Hahn L, L\u00fcbtow MM, Lorson T, Schmitt F, Appelt-Menzel A, Schobert R, et al. Investigating the influence of aromatic moieties on the formulation of hydrophobic natural products and drugs in poly (2-oxazoline)-based amphiphiles. Biomacromol. 2018;19(7):3119\u201328.","journal-title":"Biomacromol"},{"issue":"32","key":"700_CR115","doi-asserted-by":"publisher","first-page":"10980","DOI":"10.1021\/jacs.7b05376","volume":"139","author":"MM L\u00fcbtow","year":"2017","unstructured":"L\u00fcbtow MM, Hahn L, Haider MS, Luxenhofer R. Drug specificity, synergy and antagonism in ultrahigh capacity poly (2-oxazoline)\/poly (2-oxazine) based formulations. J Am Chem Soc. 2017;139(32):10980\u20133.","journal-title":"J Am Chem Soc"},{"issue":"7","key":"700_CR116","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/pat.3556","volume":"26","author":"Y Seo","year":"2015","unstructured":"Seo Y, Schulz A, Han Y, He Z, Bludau H, Wan X, et al. Poly (2-oxazoline) block copolymer based formulations of taxanes: effect of copolymer and drug structure, concentration, and environmental factors. Polym Adv Technol. 2015;26(7):837\u201350.","journal-title":"Polym Adv Technol"},{"issue":"6","key":"700_CR117","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1021\/acs.molpharmaceut.9b01117","volume":"17","author":"MM L\u00fcbtow","year":"2020","unstructured":"L\u00fcbtow MM, Oerter S, Quader S, Jeanclos E, Cubukova A, Krafft M, et al. In vitro blood-brain barrier permeability and cytotoxicity of an atorvastatin-loaded nanoformulation against glioblastoma in 2D and 3D models. Mol Pharm. 2020;17(6):1835\u201347.","journal-title":"Mol Pharm"},{"issue":"18","key":"700_CR118","doi-asserted-by":"publisher","first-page":"4972","DOI":"10.1016\/j.biomaterials.2010.02.057","volume":"31","author":"R Luxenhofer","year":"2010","unstructured":"Luxenhofer R, Schulz A, Roques C, Li S, Bronich TK, Batrakova EV, et al. Doubly amphiphilic poly (2-oxazoline)s as high-capacity delivery systems for hydrophobic drugs. Biomaterials. 2010;31(18):4972\u20139.","journal-title":"Biomaterials"},{"key":"700_CR119","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jconrel.2015.02.024","volume":"208","author":"Z He","year":"2015","unstructured":"He Z, Schulz A, Wan X, Seitz J, Bludau H, Alakhova DY, et al. Poly (2-oxazoline) based micelles with high capacity for 3rd generation taxoids: preparation, in vitro and in vivo evaluation. J Control Release. 2015;208:67\u201375.","journal-title":"J Control Release"},{"issue":"3","key":"700_CR120","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1021\/acsnano.7b07878","volume":"12","author":"X Wan","year":"2018","unstructured":"Wan X, Min Y, Bludau H, Keith A, Sheiko SS, Jordan R, et al. Drug combination synergy in worm-like polymeric micelles improves treatment outcome for small cell and non-small cell lung cancer. ACS Nano. 2018;12(3):2426\u201339.","journal-title":"ACS Nano"},{"key":"700_CR121","doi-asserted-by":"publisher","first-page":"102345","DOI":"10.1016\/j.nano.2020.102345","volume":"32","author":"D Hwang","year":"2020","unstructured":"Hwang D, Dismuke T, Tikunov A, Rosen E, Kagel J, Ramsey J, et al. Poly (2-oxazoline) nanoparticle delivery enhances the therapeutic potential of vismodegib for medulloblastoma by improving CNS pharmacokinetics and reducing systemic toxicity. Nanomedicine. 2020;32:102345.","journal-title":"Nanomedicine"},{"issue":"1","key":"700_CR122","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jconrel.2011.04.010","volume":"153","author":"R Luxenhofer","year":"2011","unstructured":"Luxenhofer R, Sahay G, Schulz A, Alakhova D, Bronich TK, Jordan R, et al. Structure-property relationship in cytotoxicity and cell uptake of poly (2-oxazoline) amphiphiles. J Control Release. 2011;153(1):73\u201382.","journal-title":"J Control Release"},{"key":"700_CR123","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.biomaterials.2016.06.002","volume":"101","author":"Z He","year":"2016","unstructured":"He Z, Wan X, Schulz A, Bludau H, Dobrovolskaia MA, Stern ST, et al. A high capacity polymeric micelle of paclitaxel: implication of high dose drug therapy to safety and in vivo anti-cancer activity. Biomaterials. 2016;101:296\u2013309.","journal-title":"Biomaterials"},{"issue":"9","key":"700_CR124","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1634\/theoncologist.2016-0459","volume":"22","author":"DL Reidy-Lagunes","year":"2017","unstructured":"Reidy-Lagunes DL, Lung B, Untch BR, Raj N, Hrabovsky A, Kelly C, et al. Complete responses to mitotane in metastatic adrenocortical carcinoma\u2014a new look at an old drug. Oncologist. 2017;22(9):1102.","journal-title":"Oncologist"},{"issue":"1","key":"700_CR125","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/CCO.0000000000000695","volume":"33","author":"G De Filpo","year":"2021","unstructured":"De Filpo G, Mannelli M, Canu L. Adrenocortical carcinoma: current treatment options. Curr Opin Oncol. 2021;33(1):16\u201322.","journal-title":"Curr Opin Oncol"},{"issue":"3","key":"700_CR126","doi-asserted-by":"publisher","first-page":"101434","DOI":"10.1016\/j.beem.2020.101434","volume":"34","author":"B Altieri","year":"2020","unstructured":"Altieri B, Ronchi CL, Kroiss M, Fassnacht M. Next-generation therapies for adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab. 2020;34(3):101434.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"700_CR127","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ando.2020.12.003","volume":"82","author":"A Vincent","year":"2021","unstructured":"Vincent A, Marie-Eve G, Rossella L, Thierry B, Yves R, Frederic C. Medical management of adrenocortical carcinoma: current recommendations, new therapeutic options and future perspectives. Ann Endocrinol. 2021;82(1):52\u20138.","journal-title":"Ann Endocrinol"},{"issue":"5","key":"700_CR128","doi-asserted-by":"publisher","first-page":"5","DOI":"10.21037\/amj.2020.01.07","volume":"5","author":"JE Hallanger-Johnson","year":"2020","unstructured":"Hallanger-Johnson JE. Systemic therapy for adrenocortical carcinoma: a review. AME Med J. 2020;5(5):5.","journal-title":"AME Med J"},{"issue":"4","key":"700_CR129","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/s12672-014-0182-1","volume":"5","author":"AM Lerario","year":"2014","unstructured":"Lerario AM, Worden FP, Ramm CA, Hasseltine EA, Stadler WM, Else T, et al. The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent\/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial. Horm Cancer. 2014;5(4):232\u20139.","journal-title":"Horm Cancer."},{"issue":"4","key":"700_CR130","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","volume":"16","author":"M Fassnacht","year":"2015","unstructured":"Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, et al. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015;16(4):426\u201335.","journal-title":"Lancet Oncol"},{"issue":"2","key":"700_CR131","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1530\/EJE-09-0804","volume":"162","author":"S Wortmann","year":"2010","unstructured":"Wortmann S, Quinkler M, Ritter C, Kroiss M, Johanssen S, Hahner S, et al. Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. Eur J Endocrinol. 2010;162(2):349.","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"700_CR132","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1210\/jc.2012-1419","volume":"97","author":"M Kroiss","year":"2012","unstructured":"Kroiss M, Quinkler M, Johanssen S, van Erp NP, Lankheet N, P\u00f6llinger A, et al. Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. J Clin Endocrinol Metab. 2012;97(10):3495\u2013503.","journal-title":"J Clin Endocrinol Metab"},{"issue":"09","key":"700_CR133","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1055\/a-0747-5571","volume":"127","author":"M Kroiss","year":"2019","unstructured":"Kroiss M, Deutschbein T, Schl\u00f6telburg W, Ronchi CL, Hescot S, K\u00f6rbl D, et al. Treatment of refractory adrenocortical carcinoma with thalidomide: Analysis of 27 patients from the European Network for the Study of Adrenal Tumours Registry. Exp Clin Endocrinol Diabetes. 2019;127(09):578\u201384.","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"4","key":"700_CR134","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1210\/jc.2013-2298","volume":"99","author":"C O'Sullivan","year":"2014","unstructured":"O\u2019Sullivan C, Edgerly M, Velarde M, Wilkerson J, Venkatesan AM, Pittaluga S, et al. The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer. J Clin Endocrinol Metab. 2014;99(4):1291\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"700_CR135","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1210\/clinem\/dgz318","volume":"105","author":"M Kroiss","year":"2020","unstructured":"Kroiss M, Megerle F, Kurlbaum M, Zimmermann S, Wendler J, Jimenez C, et al. Objective response and prolonged disease control of advanced adrenocortical carcinoma with cabozantinib. J Clin Endocrinol Metab. 2020;105(5):1461\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"700_CR136","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1530\/ERC-13-0439","volume":"21","author":"C Hantel","year":"2014","unstructured":"Hantel C, Jung S, Mussack T, Reincke M, Beuschlein F. Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model. Endocr-Relat Cancer. 2014;21(3):383\u201394.","journal-title":"Endocr-Relat Cancer."},{"issue":"2","key":"700_CR137","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1530\/JOE-11-0427","volume":"213","author":"C Hantel","year":"2012","unstructured":"Hantel C, Lewrick F, Reincke M, S\u00fcss R, Beuschlein F. Liposomal doxorubicin-based treatment in a preclinical model of adrenocortical carcinoma. J Endocrinol. 2012;213(2):155.","journal-title":"J Endocrinol"},{"issue":"10","key":"700_CR138","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1530\/ERC-16-0249","volume":"23","author":"S Jung","year":"2016","unstructured":"Jung S, Nagy Z, Fassnacht M, Zambetti G, Weiss M, Reincke M, et al. Preclinical progress and first translational steps for a liposomal chemotherapy protocol against adrenocortical carcinoma. Endocr-Relat Cancer. 2016;23(10):825\u201337.","journal-title":"Endocr-Relat Cancer."},{"key":"700_CR139","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biomaterials.2018.10.032","volume":"192","author":"X Wan","year":"2019","unstructured":"Wan X, Beaudoin JJ, Vinod N, Min Y, Makita N, Bludau H, et al. Co-delivery of paclitaxel and cisplatin in poly (2-oxazoline) polymeric micelles: implications for drug loading, release, pharmacokinetics and outcome of ovarian and breast cancer treatments. Biomaterials. 2019;192:1\u201314.","journal-title":"Biomaterials"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-021-00700-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-021-00700-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-021-00700-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T06:30:27Z","timestamp":1675578627000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-021-00700-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,21]]},"references-count":139,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["700"],"URL":"https:\/\/doi.org\/10.1007\/s13318-021-00700-5","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,21]]},"assertion":[{"value":"24 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2021","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version is updated due to request on integrate of funding note.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by Projekt DEAL. Malik Salman Haider received a PhD scholarship from the Higher Education Commission of Pakistan and German Academic Exchange Services (HEC-DAAD Pakistan). This study was further supported by the German Research Foundation [Deutsche Forschungsgemeinschaft (DFG)], project number 314061271\u2014CRC\/TRR 205, to Matthias Kroiss.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Matthias Kroiss declares that he has received travel support from HRA Pharma, the manufacturer of Lysodren<sup>\u00ae<\/sup> in Europe. Robert Luxenhofer is listed as an inventor of patents pertinent to some materials discussed in this contribution and co-founder of DelAqua Pharmaceutical Inc., which is intent on clinical development of poly(2-oxazoline)-based drug formulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"MSH had the conceptual idea for the article. The literature search was performed by MSH and TA. The first draft of the manuscript was written by MSH, and all authors commented on subsequent versions of manuscript and provided a critical revision for important intellectual content. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}